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Introduction: Fasc(;l cl~~re may pose challenges in AWR but is associated with 
decreased rates of hernia recurrence, surgical site infection and mesh infection. 
Preoperative Botulinum toxin A (BTA) injection causes temporary muscle paralysis and 
may be used as an adjunct in AWR. There are few published reports on this subject. 
We describe four unique, complex cases in which BTA can successfully be used to 
facilitate abdominal wall closure. 
Methods: Four unique cases from the Carolinas Medical Center (CMC) in which 
preoperative image-guided BTA injections were administered to the lateral abdominal 
wall musculature were reviewed. Demographics, hernia characteristics, imaging, 
surgical technique, complications and outcomes were evaluated. 
Results: For the four cases, the average BMI was 29.15±3.9kg/m2, age 58±14.8years, 
and they had 1.3±0.4 previous hernia repairs. Three patients had large ventral hernias, 
and one had a flank hernia. One patient had a previous external oblique component 
separation. Average operative data included: time to surgery from BTA injection: 
29.3±2.7 days, operative time: 252.8±101.4min, defect size: 397±279.3cm2, mesh size: 
11 04.8±365.2cm2. Mid weight polypropylene mesh was used in all cases and primary 
fascial closure was achieved in all patients. There were no postoperative complications. 
With an average follow up time of 18±12.8 months, there are no recurrences. 
Conclusion: BTA injection into the lateral abdominal wall musculature should be 
considered in certain challenging AWR cases in order to reap proximate the muscular 
fascia. Preoperative BTA injection appears to be a minimally invasive, safe, and 
effective technique in facilitating primary fascial closure in cases where component 
separation may not be adequate, possible, or previously failed. 
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Process Analysis Statement 
During the summer of 2016, I was fortunate enough to be selected for an 
internship with the Carolinas Laparoscopic and Advanced Surgery Program at the 
Carolinas Medical Center in Charlotte, North Carolina. Through this opportunity, I was 
able to observe lab testing for active and ongoing studies, shadow surgeons in the 
operating room, contribute to weekly research meetings, and work closely with world-
class physicians on research projects. The main research project I became involved 
with had to do with examining the novel use of Botulinum Toxin A (Botox) in complex 
abdominal wall reconstruction cases -this is where the idea for this thesis came from. I 
was given the arduous task of combing through medical records of all recent patients 
who had undergone this procedure, and then conducting a retrospective chart review 
and analysis of each one. 
Over the span of ten weeks, not only did I have to collect and analyze large 
amounts of data for each patient, but I also had to do a vast amount of research on the 
background of the procedure itself. As a college student with very minimal medical 
experience compared to the physicians I was working with, I came into this project at a 
severe disadvantage from a knowledge perspective, and had to face the challenge of 
simply not knowing much of what my mentors considered basic information. To combat 
this challenge, I dedicated a majority of my time to research - I researched the 
Botulinum Toxin itself, the theory and process of an abdominal wall reconstruction, 
surgical terminology, how Botox was administered, how to efficiently read a medical 
chart, etc. Through many hours of sifting through articles, observing the procedures 
being performed, asking questions, and analyzing data, I became incredibly well versed 
in a very unique procedure that has only been performed a handful of times throughout 
the entire world. After my internship ended, I simply wasn't ready to forego my 
involvement. When I returned to Ball State for my senior year, I told the physicians in 
Charlotte that I wanted to keep working on the project I had invested so much time in 
and began finishing up the research and writing a manuscript. Thus, my thesis was 
born. 
Throughout this long process, I have grown immensely as a researcher and a 
writer. Clinical research has always been an interest of mine, and I hope to make it an 
integral part of my future medical career. Receiving the opportunity to work with and be 
mentored by such distinguished medical professionals as these has not only opened my 
eyes to the importance of clinical research, but has also taught me the best ways to 
conduct it - an invaluable asset as I enter into medical school. This thesis is essentially 
the culmination of everything I have learned thus far involving research and scientific 
writing, and I consider it to be the official beginning of my medical career. 
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Introduction 
lncisional ventral hernias occur in approximately 20% of all patients undergoing 
laparotomi ·2·3, a rate that has been show to increase by as much as 15% in higher risk 
patients who suffer from obesity and other comorbidities4•5 . Despite advances in 
surgical technique and the utilization of mesh, the rate of hernia recurrence continues to 
be significant, especially for patients who have undergone previous failed repair and 
have larger defects as the size of defect is largely correlated with the risk of recurrence 
and chance of hernia repair failure6 . Cost associated with repair of ventral hernias and 
complications arising from them are substantial7 . Poulose et al.7 examined the number 
of ventral hernia repairs performed in the US and their associated costs from 2001-
2006, and found that even a 1% reduction in recurrence rates and the need for 
reoperation would save $32 million annually. The second most common reason for 
readmission to the hospital after any surgical procedure in the United States is a VHR8 . 
In an assessment of 794 patients, Holihan et al. 9 demonstrated that patients who had 
undergone multiple previously failed repairs had a higher rate of reoperation, surgical 
site infection, operative duration, and hernia recurrence- the authors demonstrated a 
73% recurrence rate in patients who underwent their third incisional hernia repair9. 
Abdominal wall reconstruction for complex ventral hernias can often be 
challenging due to loss of domain, size of hernia, and previous abdominal wall 
reconstruction. Loss of domain of the abdominal wall refers to cases in which at least 
15-20% of the intraabdominal contents are outside the peritoneal cavity 10·11 . It is an 
issue often encountered in complex hernia repair procedures 11 , and one that remains a 
significant challenge to abdominal wall closure due to having to replace the contents of 
· the hernia sac to the abdominal cavity, leading to increased abdominal wall tension 12. In 
addition to difficulties when performing fascial closure, abdominal wall tension leads to 
increased postoperative morbidity and hernia recurrence6·13. Excessive abdominal wall 
tension after VHR may result in a recurrence through disruption of the midline and 
subsequent lateral abdominal wall muscular contraction, followed by retraction of the 
fascial edges 14. Bridging or inlay mesh repair of ventral hernia defects carries a high 
recurrence rate and has demonstrated to be inferior to sublay, retrorectus and onlay 
mesh placement positions with regard to recurrence and surgical site infections 15-18. 
Efforts to achieve fascial closure over mesh repair include component separation. While 
myofascial component separation successfully accomplishes release of the scarred and 
restricted abdominal wall14 , some patients will require additional advancement to allow 
myofascial reapproximation. Furthermore, no standard of care or long term evaluations 
exist to indicate the safety of rereleasing the oblique musculature. 
McAdory et al.19 and others have attempted to combat this issue using 
progressive preoperative pneumoperitoneum (PPP) as a pneumatic tissue expander, 
pressurizing the abdomen to prepare patients with loss of domain for repair. While the 
overall recurrence rate associated with PPP use has been shown to range from 2.6-
5%·19·20·21 , it does have increased costs and risks like pulmonary mycetoma, deep 
venous thrombosis, acute renal failure, port infection, and others 19. In addition, Sabbagh 
et al13 demonstrated that PPP can also stretch the muscles and hernia sac, especially in 
cases where the abdominal muscles are significantly retracted . 
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lntraabdominal injections of Botulinum Toxin A (BTA) have been shown to 
improve outcomes and reduce muscle tension. BTA is a neurotoxin isolated from the 
bacterium Clostridium botulinum14. It is most commonly used for cosmetic procedures, 
dystonias, some pain management, and spasticity related disorders7. BTA functions by 
acting as a cholinergic neuromuscular antagonist, which obstructs the release of 
acetylcholine at the neuromuscular junction, leading to short term flaccid muscle 
paralysis for up to 6 months22·23. In a prospective study of 27 patients undergoing 
ultrasound guided BTA injections, Elstner et al.6 described that BTA can be used as an 
aide for myofascial relaxation in the lateral wall of the abdomen, lengthening and 
thinning the muscles. Abdominal oblique muscle paralysis has been shown to decrease 
fascial defects and facilitate abdominal wall closure with minimal tension6. 
While several studies have described the effect BTA has on fascial closure, 
lateral abdominal muscle length and thickness, and post-operative pain, there is very 
minimal literature that reviews BTA's effect on hernia recurrence, especially in higher 
risk patients. We report a series of four unique cases of abdominal wall reconstruction 
where BTA injection to the lateral abdominal musculature was used to minimize the rate 
of hernia recurrence and postoperative complications, as there were no other 
reconstructive options available to obtain myofascial reapproximation. 
Methods 
Four unique cases where BTA was utilized were selected to demonstrate the 
utility of Botox in cases where other reconstruction methods were not favorable. 
Approximately one month prior to surgery, the patients presented to interventional 
radiology and underwent CT guided BTA injections into the lateral abdominal wall 
musculature. Local anesthetic was utilized and 22-gauge spinal needles were 
advanced into anterior and posterior sections of the transverse abdominis, internal 
oblique, and external oblique muscles. The amount of BTA varied for each case, 
ranging from 100- 300 units (5 units/cc sterile saline) and 2-4 equidistant sites were 
selected near the rib cage and iliac crest on each side of the abdomen depending on 
the specific case. On average, 150 units were injected per side, with about 7 units per 
injection. 
Measurements of the hernia sac volume (HSV) and abdominal cavity volume 
(ACV) as well as the volume ratio (VR=HSV/ACV) were obtained as described by 
Tanaka et al.24 for the patients with a loss of domain (Patient 1 and 4). 
Case Reports 
Case 1 
A 61-year-old man with extensive history of trauma and a previously failed hernia 
repair with associated postoperative infection presented to our hernia referral center 
with a massive ventral hernia with loss of domain including patients entire small and 
large intestine, stomach, and part of pancreas (Fig. 1 & 2). The patient's BMI was 33 
kg/m2, and he had a history of coronary artery disease and tobacco use. On CT (Fig. 2) 
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maximal width of the defect was 17 em. The hernia volume ratio was 16.5%. [Hernia (cc 
x ap x transverse) =20.6 x 6.9 x 17.6; Abdomen =38.9 x 12.6 x 30.9; HSV=1300.9; 
ACV=7875.6; VR=16.5%]. 
Given the extensive size of the defect and large loss of domain, the patient was 
counseled to lose weight preoperatively and BTA injections were recommended to 
facilitate abdominal closure. 
The patient lost 22 pounds, quit smoking, and presented for surgery one month 
after the BTA injections. He underwent an open ventral hernia repair with mesh, 
including bilateral external oblique and posterior rectus sheath release. Intraoperatively, 
the defect measured 29x27cm, and mesh overlap was achieved by sewing two 
25x35cm meshes together to make a 50x35cm mesh. The mesh was placed in a 
preperitoneal location and fascia was closed over the mesh in the midline. The patient 
has had no wound complications and no recurrence within 3 months of follow up. 
A 8 
c D 
Figure 1. 
Case 1: Preoperative ventral photograph A, Preoperative lateral photograph B, Intraoperative 
photographs C & D 
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Figure 2. 
Case 1: Preoperative CT scans A & 8 
Case 2 
A 75-year-old woman with history of right colectomy and two subsequent failed 
ventral hernia repairs, including a bilateral external oblique myofascial release. She 
presented with a multiply recurrent right abdominal wall hernia (Fig. 4). Her BMI was 
22.89 kg/ m2 and the defect measured 13 x 10 em on CT (Fig. 3). Due to the large 
defect to body size ratio and a previously failed component separation, BTA injections 
were recommended. 
The patient presented for surgery one month after the BTA procedure. She 
underwent an open ventral hernia repair with preperitoneal mesh. The mesh was 30x29 
em and the fascia was closed without the need to perform myofascial release. The 
patient did not have any postoperative wound complications and there has been no 
evidence of hernia recurrence with one year of follow up. 
A B 
Figure 3. 
Case 2: Preoperative CT images A & 8 
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Figure 4. 
Case 2: Preoperative photograph of right abdominal wall hernia 
Case 3 
A 57-year-old man with history of open right partial nephrectomy for renal cell 
cancer in 2011 and subsequent flank hernia presented with a symptomatic, recurrent 
flank hernia. The patient had a previous failed repair in 2012 with polypropylene mesh. 
He had a large lateral defect measuring 10 em on CT (Fig. 5A) as well as retraction of 
his oblique muscles to his iliac crest. The width of his right oblique muscles was almost 
five centimeters due to the muscle retraction. His BMI was 29.02 kg/m2. Because of the 
extensive contraction of the lateral abdominal wall musculature, BTA injections were 
recommended and only required on one side of the abdomen. 
The patient presented for surgery one month after the procedure, having lost 9 
lbs, and underwent an open flank hernia repair. The defect measured 13x1 Ocm and a 
28x28cm mesh was used in the preperitoneal position. No component separation was 
needed to accomplish closure of this lateral defect. He had no postoperative 
complications and at 23-month follow-up, there has been no evidence of recurrence. 
A B 
Figure 5. 
Case 3: Preoperative CT A, Postoperative photograph 8 
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Case4 
A 32-year old man with history of blunt abdominal trauma from a fall , multiple 
laparotomies, and eventual takedown of enterocutaneous fistula, presented with a large 
abdominal wall defect and loss of domain (Fig 6A & 68). The patient's BMI was 31.17 
kg/m2 and on CT (Fig. 6C) the defect width measured 15.5 em. The hernia volume ratio 
was 22.4%. [Hernia (cc x ap x transverse) =30.5 x 5.5 x 15.5; Abdomen =40.2 x 11.9 x 
24.3; HSV=1352.1 ; ACV=6044.8; VR=22.4%] 
BTA injections were recommended. One month post BTA, a repeat CT was 
obtained demonstrating a defect size decrease by 30% (from 15.5 em to 1 0 em in 
width). The patient subsequently had an open ventral hernia repair with mesh. 
Intraoperatively, the defect measured 15x25cm and a bilateral transversus abdominus 
muscle release was performed to facilitate midline closure over a 30x35cm mid weight 
polypropylene mesh. The patient did not have any postoperative wound complications 
or recurrence at 6 months follow up. 
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Figure 6. 
Case 4: Preoperative ventral photographA, Preoperative lateral photograph B, Preoperative CT C, 
BT A injection before ventral hernia repair D 
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Figure 7. 
Case 4: 4 weeks postoperative A, 6 month postoperative CT B, 1 year postoperative 
photograph C 
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Results 
Four unique hernias are presented here to demonstrate the utilization of pre-
operative BTA injections to the abdominal wall musculature and subsequent abdominal 
wall reconstruction. Mean age was 58±14.8 years (range 35-62). Mean BMI at initial 
consultation was 29.15±3.9 kg/m2 (range 22-33) and 26.45±2.5 kg/m2 at the time of 
operation after preoperative weight loss. All 4 patients had at least one previous failed 
repair (mean 1.3±0.4) with one patient having had previous external oblique component 
separation. The mean defect area was 397±279.3 cm2 (range 130-783 cm2) and the 
average mesh size 1104.8±365.2 cm2 . BTA injections were performed on average 
29.3±2. 7 days before surgery. Mean operative time was 252.8±1 01.4 minutes (range 
148-395 min). Myofascial reapproximation was achieved in all cases, and there were no 
subsequent major preoperative or postoperative complications, including no surgical 
site infections. All BTA treatments were well tolerated. All patients regained normal 
abdominal muscle function. Mean follow-up was 18±12.8 months (range 2-36 months), 
and there has been no evidence of hernia recurrence in any of the patients to date. 
Discussion 
Elective ventral hernia operations in patients with comorbidities are costly in 
multiple ways. An increase in obesity and diabetes in the population has certainly made 
hernia repairs more challenging . Even with component separations, some defects 
cannot be closed and leave surgeons without good options. Bridging or inlay repair of 
ventral hernia defects is associated with the highest recurrence and complication 
rate15·16·17. Booth et al.16 demonstrated that bridged repairs were associated with higher 
risk of hernia recurrence (56% vs 8%), as well as a higher complication rate (74% vs 
32%). Any subsequent repair has a higher odds of failing and is costly both from the 
standpoint of quality of life and hospital charges and disability. The authors have 
previously demonstrated the increased cost of wound complications after complex 
ventral hernia repair. A complex ventral hernia repair without complications yielded 
$40,100 in patient charges, including inpatient charges and all inpatient and outpatient 
follow-up for general surgery, plastic surgery, radiology, and infectious disease. 
Patients with wound infections had mean charges of $85,400, and patients with mesh 
infections had mean charges of $146,200. This is an increased cost of over $100,000 
for a mesh infection compared to a patient with no complications25. Although BTA 
charges, on average, were around $3,000, this is miniscule when compared to the cost 
of hernia recurrence or infection in any patient, particularly in the patients described in 
this case series, whose reconstruction options were extremely limited. 
The application of BTA in the abdomen is one of the few promising alternatives to 
surgical techniques like component separation for minimizing muscle tension during 
abdominal wall closure after VHR14. Cakmak et al.26 was the first to report on the use of 
BTA in the abdomen by using an animal model. The study demonstrated BTA's ability to 
increase abdominal wall volume and decrease muscle activity in rats, effectively 
alleviating abdominal pressure and decreasing the chance of abdominal compartment 
syndrome26. 
9 
When other reconstructive options for VHR do not exist and a bridging mesh 
repair or rerelease of oblique musculature are the only options, BTA injection should be 
considered to decrease postoperative complications and hernia recurrence. In patients 
who have undergone both component separation and transverse abdominis muscle 
release (TAR), recurrence poses a complex challenge as lateral hernias are difficult to 
repair and there may be skin and subcutaneous tissue that compromises the ability to 
make other incisions27. 
Recent studies from Zielinski et al28 and lbarro-Hutardo et al22 demonstrate the 
effect of BTA injected in the human abdomen. Focusing primarily on its ability to 
enhance primary closure, Zielinski28 demonstrated a primary fascial closure rate of 83% 
in 18 patients who underwent "chemical components separation" using BTA prior to 
open hernia repair. Looking at actual defect size, lbarro-Hutardo et al.22 found an overall 
mean reduction of transverse hernia defect size by 5.25 ± 2.35 em in 12 patients who 
received BTA injections from an original mean defect size of 13.85 ± 1.49 em. ACT 
scan was performed before BTA injection and 4 weeks after, and component separation 
was performed in half of the cases. A follow-up study by the same group demonstrated 
a decrease in the thickness of the lateral abdominal wall muscles by an average of 1 em 
after BTA application, and an average increase of 2.44 em in lateral abdominal wall 
muscle length 14. These changes in the abdominal wall resulting from the paralysis 
allowed fascial closure at the midline to be completed in all cases 14. By decreasing 
midline tension through muscle paralysis, BTA has the ability to facilitate closure and 
diminish one of the main factors in failed hernia repairs6 . 
Despite innovation in surgical techniques and meshes, large defects and 
previous failed repairs considerably increase the already significant chance of hernia 
recurrence. Considerations for future repairs, complications associated with each 
recurrence, quality of life of patients, and costs associated are substantial8·9 . Recurrent 
repair diminishes abdominal tissue quality; the recurrence rate has been shown to 
increase from 24% after the first repair, to 35% and 39% after the second and third , 
respectivell·12. The present series demonstrates that preoperative BTA injection can be 
considered to help reduce tension in the abdominal wall musculature and allow for 
fascial closure, an important predictor of success in hernia repair. While BTA's 
predominant use over the last 40 years has been in spastic muscle disorders and 
cosmetic procedures, recent additional studies29 , as well as the present study, 
demonstrate BTA as an adjunct for abdominal wall surgery. 
In addition, BTA has also been shown to have potential as a successful pain 
modulator. Smoot et al. 30 reported a case study in which patient's postoperative pain 
improved substantially after BTA injection. Zendejas et al31 performed a quantitative 
experiment, examining opioid usage and postoperative pain. When comparing 24 
patients who underwent BTA injections to patients who had not, they reported a 64% 
reduction in opioid usage on fifth postoperative day in patients who underwent the BTA 
treatment. 
These four cases illustrate unique examples where complex abdominal wall 
reconstruction can be greatly aided with BTA and is likely in part responsible for good 
patient outcomes. BTA should be studied further in appropriate patients and with long 
term follow-up. 
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Conclusion 
Preoperative BTA injection is a safe and an effective method to obtain myofascial 
reapproximation and should be considered for complex abdominal wall reconstruction to 
avoid fascial bridging, especially in cases where previous component separation had 
been performed and with very large hernias with loss of domain. Defining the 
appropriate population is the goal of this study. BTA in patients undergoing abdominal 
surgery holds a promise and merits further investigation in hernia repair. 
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